 | Up a level |
Belau, A., du Bois, A., Sehouli, J., Reuss, A., Lampe, B., Meier, W., Stuth, R., Forner, D. M., Elling, D., Denschlag, D., Pfisterer, J., Gnauert, K., Armin, B., von Koch, F. E., Valter, M., Mahner, S., Runnebaum, I. B., Schmalfeldt, B., Wagner, U. and Harter, P. (2018). lion-lymphadenectomy in ovarian neoplasms.a prospective randomized ago study group led gynecologyc cancer intergroup trial. Oncol. Res. Treat., 41. S. 13 - 14. BASEL: KARGER. ISSN 2296-5262
Sehouli, J., Mahner, S., Neunhoeffer, T., Harter, P., de Gregorio, N., Fridrich, C., Markmann, S., Richter, R., Potenberg, J., Lorenz, R., Schmidt, M., Doering, G., Belau, A., Lueck, H. J., Chekerov, R., du Bois, A. and Hilpert, F. (2016). Topotecan (T) +/- Sorafenib (S) for platinum-resistant ovarian cancer (PROC): results of doubleblind placebo-controlled randomized NOGGO - AGO intergroup trial. Int. J. Gynecol. Cancer, 26. S. 2 - 4. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1525-1438